Merrimack Pharma Stock Price (NASDAQ:MACK)

Add to My Stocks
$3.16 $0.02 (0.63%) MACK stock closing price Feb 21, 2017 (Closing)
Merrimack Pharma
21 FEB 2017
amigobulls logo
MACK hand_up
MACK vs S&P 500
Closing Price: Feb 21, 2017
$3.16 ( -0.63%)
S&P 500
2365.4 ( 0.6%)
52 Week Price Range
1 Year Return: -42.6%
Q3 Growth*
Profitable ?
net image
2016 Q3 Net Loss
home image
☆ ☆ ☆ ☆ ☆★ ★ ★ ★ ★
Double Tap To Exit Full Screen

Merrimack Pharma Snapshot Video

15 5 2

MACK Stock Details

Prev Close* : $3.18
Market Cap:
Day Low: $3.12
52 Week Low: $2.83
Open: $3.16
Volume: 1643073
Day High: $3.2
52 Week High: $9.02

Latest Stock Market News

Latest Articles

Merrimack Pharma News - From Partners

MACK Stockcharts

View MACK PE ratio, PS ratio stocks charts and compare with peers.
MACK Chart
Note: Compare Merrimack Pharma stock price history with the index and industry peers.

Merrimack Pharma Valuation

PS ratio (
price to sales ratio

Merrimack Pharma Financial Ratios

Asset Turnover
Receivables Turnover

MACK Industry Peers

Company Price Change (%)
American Brivision (ABVC)20 (0%)
Merus (MRUS)25.220.22 (0.88%)
Baxter International (BAX)49.960.23 (0.46%)
Aduro Biotech (ADRO)11.80 (0%)
Newlink Genetics (NLNK)14.90.37 (2.42%)
Immune Pharma (IMNP)0.190 (0%)
Fibrogen (FGEN)24.350.25 (1.02%)

Top Stock Gainers

show top losers
CompanyPriceChange (%)
EXACT Sciences (EXAS)22.412.5 (12.56%)
Fate Therapeutics (FATE)4.380.45 (11.45%)
Nymox Pharmaceutical (NYMX)3.540.12 (3.51%)
Myriad Genetics (MYGN)19.080.46 (2.47%)
Stemline Therapeutics (STML)6.950.15 (2.21%)
Evogene (EVGN)5.4210.11 (2.07%)
OncoMed Pharma (OMED)8.910.18 (2.06%)
Top gainers from Medical-Biomed-Genetics industry
* As of Feb 21, 2017
CompanyPriceChange (%)
Trevena (TRVN)4.272.86 (40.11%)
Momenta Pharma (MNTA)16.052.95 (15.53%)
Peregrine Pharma (PPHM)0.4790.07 (12.73%)
Cytokinetics (CYTK)10.40.85 (7.56%)
Argos Therapeutics (ARGS)4.40.3 (6.38%)
Sorrento Therapeutics (SRNE)5.250.3 (5.41%)
Immunomedics (IMMU)5.060.28 (5.24%)
Top losers from Medical-Biomed-Genetics industry
* As of Feb 21, 2017

Merrimack Pharma Financial Statements

income statement20152014201320122011
Net Sales Or Revenues89.25M102.75M47.78M48.92M34.21M
Net Income-147.95M-83.29M-130.92M-91.27M-79.22M
Total Operating Expense218.77M169M168.31M141.65M115.08M
view Merrimack Pharmaceuticals Inc income statement
balance sheet20152014201320122011
Total Assets234.88M158.65M192.41M148.97M85.29M
Total Liabilities418.8M260.79M235.88M155.39M106.99M
Shareholders Equity-183.92M-102.14M-43.46M-6.42M-21.69M
view Merrimack Pharmaceuticals Inc balance sheet
cash flow statement20152014201320122011
Net Increase (Decrease) In Assets Liabilities14.57M23.1M14.98M-5.99M13.18M
Net Cash From (Used By) Operating Activities-105.35M-34.8M-95.17M-79.81M-52.81M
Increase (Decrease) In Prop Plant And Equipment-12.78M-6.03M-9.85M-3.18M-3.75M
view Merrimack Pharmaceuticals Inc cashflow statement

Merrimack Pharmaceuticals Inc Stock News - Partner Headlines

Merrimack Pharma Stock Message Board

Merrimack Pharma stock price ended the last trading day at 3.18. Stock price or share price can be used to find the total market value of a company. Merrimack Pharma market cap stands at 414.72M as of 17 Feb, 2017. Merrimack Pharma valuation can be guaged using various valuation metrics like the price to earnings ratio.

For recognizing and analyzing the real performance of Merrimack Pharma stock, it is a standard practise to adjust historical stock prices to remove gaps caused by stock splits, dividends and distributions. 1123509 MACK shares were traded yesterday, and Merrimack Pharma stock chart shows that the MACK stock quote hit a day high of 3.23 and day low of 3.15. Dividends are usually paid by large stable companies, and typically not by those which are in their rapid growth stages. A company's continuing success is indicated by a steadily increasing dividend payout. To check the historical stock price movement, all time high, and all time low of MACK, view Merrimack Pharma stock price history.